PMID- 38199906
OWN - NLM
STAT- MEDLINE
DCOM- 20240312
LR  - 20240312
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Linking)
VI  - 60
IP  - 5
DP  - 2023 Nov
TI  - Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment 
      of LBCL in 2023.
PG  - 322-328
LID - S0037-1963(23)00095-1 [pii]
LID - 10.1053/j.seminhematol.2023.12.002 [doi]
AB  - Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell 
      therapy has profoundly changed the management of relapsed/refractory large-B-cell 
      lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell 
      products for LBCL: axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel 
      (liso-cel), and tisagenlecleucel (tisa-cel). Two of these (axi-cel & liso-cel) 
      are approved for use in the second-line setting under certain conditions. As CAR 
      T-cell therapy continues to define a new role in the treatment armamentarium for 
      LBCL, questions remain regarding which product to use and how to sequence CAR 
      T-cell therapy with other therapeutic options. Here we will briefly review the 
      key features of each FDA-approved anti-CD19 CAR T-cell product and the data that 
      led to regulatory approval for each. Next, we will focus on the recent landmark 
      studies that have established the use of CAR T-cell therapy as second-line 
      treatment. While no direct prospective head-to-head comparisons exist of the 3 
      constructs, we will review some retrospective studies that suggest some emerging 
      differences between the products. Lastly, we will turn our attention to the 
      horizon as we explore some of the ongoing questions of how to best leverage the 
      curative potential of CAR T-cell therapy for the most effective management of 
      LBCL. These areas include the consideration of CAR T-cell therapy in the 
      frontline setting, the optimal timing for CAR T-cell referral, the optimal 
      bridging approach, and how to continue advancing novel CAR T-cell approaches in 
      the context of the current treatment landscape.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Ryan, Christine E
AU  - Ryan CE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 
      Electronic address: Caron_Jacobson@DFCI.Harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20231212
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Prospective Studies
MH  - *Receptors, Chimeric Antigen
MH  - Retrospective Studies
MH  - Cell- and Tissue-Based Therapy
MH  - *Lymphoma, Large B-Cell, Diffuse
COIS- Declaration of competing interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: CER: Received honoraria from Research to Practice, Curio Science, and 
      AstraZeneca. CAJ: Received consulting fees from Kite/Gilead, Novartis, 
      BMS/Celgene, Instil Bio, ImmPACT Bio, Caribou Bio, Abintus Bio, Miltenyi, Ipsen, 
      Morphosys, ADC Therapeutics, Abbvie, AstraZeneca, Synthekine, Sana, 
      Daiichi-Sankyo; received research funding from Kite/Gilead, Pfizer.
EDAT- 2024/01/11 00:42
MHDA- 2024/03/12 06:43
CRDT- 2024/01/10 21:56
PHST- 2023/09/05 00:00 [received]
PHST- 2023/11/30 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2024/03/12 06:43 [medline]
PHST- 2024/01/11 00:42 [pubmed]
PHST- 2024/01/10 21:56 [entrez]
AID - S0037-1963(23)00095-1 [pii]
AID - 10.1053/j.seminhematol.2023.12.002 [doi]
PST - ppublish
SO  - Semin Hematol. 2023 Nov;60(5):322-328. doi: 10.1053/j.seminhematol.2023.12.002. 
      Epub 2023 Dec 12.